K A L McAllister1,2,3, A C Mar4,5, D E Theobald4,5, L M Saksida4,5, T J Bussey4,5. 1. University of Cambridge Department of Psychology, Downing Street, Cambridge, CB2 3EB, UK. kalmcallister@gmail.com. 2. MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK. kalmcallister@gmail.com. 3. , 20 Manchester Sq., London, W1U 3PZ, UK. kalmcallister@gmail.com. 4. University of Cambridge Department of Psychology, Downing Street, Cambridge, CB2 3EB, UK. 5. MRC and Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, CB2 3EB, UK.
Abstract
RATIONALE: It is becoming increasingly clear that the development of treatments for cognitive symptoms of schizophrenia requires urgent attention, and that valid animal models of relevant impairments are required. With subchronic psychotomimetic agent phencyclidine (scPCP), a putative model of such impairment, the extent to which changes following scPCP do or do not resemble those following dysfunction of the prefrontal cortex is of importance. OBJECTIVES: The present study carried out a comparison of the most common scPCP dosing regimen with excitotoxin-induced medial prefrontal cortex (mPFC) dysfunction in rats, across several cognitive tests relevant to schizophrenia. METHODS: ScPCP subjects were dosed intraperitoneal with 5 mg/kg PCP or vehicle twice daily for 1 week followed by 1 week washout prior to behavioural testing. mPFC dysfunction was induced via fibre-sparing excitotoxin infused into the pre-limbic and infralimbic cortex. Subjects were tested on spontaneous novel object recognition, touchscreen object-location paired-associates learning and touchscreen reversal learning. RESULTS: A double-dissociation was observed between object-location paired-associates learning and object recognition: mPFC dysfunction impaired acquisition of the object-location task but not spontaneous novel object recognition, while scPCP impaired spontaneous novel object recognition but not object-location associative learning. Both scPCP and mPFC dysfunction resulted in a similar facilitation of reversal learning. CONCLUSIONS: The pattern of impairment following scPCP raises questions around its efficacy as a model of cognitive impairment in schizophrenia, particularly if importance is placed on faithfully replicating the effects of mPFC dysfunction.
RATIONALE: It is becoming increasingly clear that the development of treatments for cognitive symptoms of schizophrenia requires urgent attention, and that valid animal models of relevant impairments are required. With subchronic psychotomimetic agent phencyclidine (scPCP), a putative model of such impairment, the extent to which changes following scPCP do or do not resemble those following dysfunction of the prefrontal cortex is of importance. OBJECTIVES: The present study carried out a comparison of the most common scPCP dosing regimen with excitotoxin-induced medial prefrontal cortex (mPFC) dysfunction in rats, across several cognitive tests relevant to schizophrenia. METHODS: ScPCP subjects were dosed intraperitoneal with 5 mg/kg PCP or vehicle twice daily for 1 week followed by 1 week washout prior to behavioural testing. mPFC dysfunction was induced via fibre-sparing excitotoxin infused into the pre-limbic and infralimbic cortex. Subjects were tested on spontaneous novel object recognition, touchscreen object-location paired-associates learning and touchscreen reversal learning. RESULTS: A double-dissociation was observed between object-location paired-associates learning and object recognition: mPFC dysfunction impaired acquisition of the object-location task but not spontaneous novel object recognition, while scPCP impaired spontaneous novel object recognition but not object-location associative learning. Both scPCP and mPFC dysfunction resulted in a similar facilitation of reversal learning. CONCLUSIONS: The pattern of impairment following scPCP raises questions around its efficacy as a model of cognitive impairment in schizophrenia, particularly if importance is placed on faithfully replicating the effects of mPFC dysfunction.
Authors: Ben Grayson; Lisa Adamson; Michael Harte; Marianne Leger; Samuel Marsh; Chloe Piercy; Joanna C Neill Journal: Behav Brain Res Date: 2014-03-13 Impact factor: 3.332
Authors: Nagi Idris; Jo Neill; Ben Grayson; Benny Bang-Andersen; Louise M Witten; Lise Tøttrup Brennum; Jørn Arnt Journal: Psychopharmacology (Berl) Date: 2009-10-23 Impact factor: 4.530
Authors: Gregory B Bissonette; Gabriela J Martins; Theresa M Franz; Elizabeth S Harper; Geoffrey Schoenbaum; Elizabeth M Powell Journal: J Neurosci Date: 2008-10-29 Impact factor: 6.167
Authors: Jonathan L Brigman; Jessica Ihne; Lisa M Saksida; Timothy J Bussey; Andrew Holmes Journal: Front Behav Neurosci Date: 2009-02-23 Impact factor: 3.558
Authors: M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey Journal: Psychopharmacology (Berl) Date: 2015-07-24 Impact factor: 4.530
Authors: Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-07-06 Impact factor: 5.067
Authors: R Hadar; L Bikovski; M L Soto-Montenegro; J Schimke; P Maier; S Ewing; M Voget; F Wieske; T Götz; M Desco; C Hamani; J Pascau; I Weiner; C Winter Journal: Mol Psychiatry Date: 2017-04-04 Impact factor: 15.992
Authors: M E Hervig; L Fiddian; L Piilgaard; T Božič; M Blanco-Pozo; C Knudsen; S F Olesen; J Alsiö; T W Robbins Journal: Cereb Cortex Date: 2020-03-14 Impact factor: 5.357
Authors: Johan Alsiö; Olivia Lehmann; Colin McKenzie; David E Theobald; Lydia Searle; Jing Xia; Jeffrey W Dalley; Trevor W Robbins Journal: Cereb Cortex Date: 2021-01-05 Impact factor: 5.357